AIA
LGND icon

Avalon Investment & Advisory’s Ligand Pharmaceuticals LGND Stock Holding History

Avalon Investment & Advisory’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-22,028
Closed -$3.77M – 329
2018
Q3 		$3.77M Buy
22,028
+1,558
+8% +$235K 0.11% 175
2018
Q2 		$2.65M Buy
20,470
+1,848
+10% +$206K 0.08% 204
2018
Q1 		$1.92M Buy
+18,622
New +$1.84M 0.06% 219

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Avalon Investment & Advisory's LGND Position: Q4 2018 in Review

Avalon Investment & Advisory sold out of Ligand Pharmaceuticals (LGND) in Q4 2018, closing a stake of 22,028 shares — an estimated $3.77M sold.

Avalon Investment & Advisory first reported a position in LGND in Q1 2018 and held it in 3 quarters. The position peaked at $3.77M in Q3 2018. 362 funds tracked by Wall St. Rank hold LGND as of Q4 2018.

  • Avalon Investment & Advisory reported no remaining Ligand Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Avalon Investment & Advisory sold 22,028 Ligand Pharmaceuticals shares in Q4 2018, an estimated $3.77M.
  • Avalon Investment & Advisory first reported a position in Ligand Pharmaceuticals in Q1 2018 and held it in 3 quarters.
  • Avalon Investment & Advisory's Ligand Pharmaceuticals position peaked at $3.77M in Q3 2018.
  • 362 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2018.

Based on Avalon Investment & Advisory's 13F filing for Q4 2018, filed 14 Feb 2019.